BioTuesdays

Tag - Michal Higgins

Viridian

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.